Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Qingke beta-glucan** is a naturally occurring high-molecular-weight polysaccharide isolated from Qingke (Tibetan hulless barley, Hordeum vulgare L. var. nudum) and characterized by β-(1→4) glucan main chains and β-(1→3) side chains[1][5]. It is primarily investigated as a functional food and nutraceutical ingredient, not a pharmaceutical drug. Mechanistically, Qingke beta-glucan acts by increasing intestinal viscosity, interacting with starch and amylose, and inhibiting digestive enzymes including α-glucosidase and α-amylase[1][5]. This inhibition can slow glucose absorption and lower postprandial glycemic response, supporting its hypoglycemic potential[1][5]. Additionally, Qingke beta-glucan exhibits antioxidant activity, anti-inflammatory effects, and may modulate gut microbiota to reduce neuroinflammation and promote cognitive health[2][3][4]. In animal studies, it improves metabolic parameters (cholesterol, glucose, body weight) and ameliorates Alzheimer’s disease-associated cognitive decline[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingke beta-glucan.